BBLG — Bone Biologics Balance Sheet
0.000.00%
Last trade - 00:00Annual balance sheet for Bone Biologics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 6.68 | 7.54 | 3.03 | 3.33 | 5.33 |
| Net Total Receivables | — | — | — | — | 0.01 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 6.68 | 8.5 | 3.74 | 3.86 | 5.8 |
| Total Assets | 6.68 | 8.5 | 3.74 | 3.86 | 5.8 |
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 0.1 | 2.55 | 0.831 | 0.378 | 0.419 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 0.1 | 2.55 | 0.831 | 0.378 | 0.419 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 6.58 | 5.95 | 2.91 | 3.48 | 5.38 |
| Total Liabilities & Shareholders' Equity | 6.68 | 8.5 | 3.74 | 3.86 | 5.8 |
| Total Common Shares Outstanding |